Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 6, 2023 THOUSAND OAKS, Calif.–(BUSINESS WIRE)—- $ATRA #CART–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 6,250 restricted stock units of Atara’s common stock to one newly hired […]
Evolus to Report First Quarter 2023 Results and Provide Business Update
May 5, 2023 NEWPORT BEACH, Calif.–(BUSINESS WIRE)—- $EOLS–Evolus, Inc. announces that it will report its first quarter 2023 financial results and provide a business update on Tuesday, May 9, 2023. Go to Source Author:
Fulgent Reports First Quarter 2023 Financial Results
May 5, 2023 EL MONTE, Calif.–(BUSINESS WIRE)–Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2023. First Quarter 2023 Results: Total Revenue of $66.2 million Core Revenue1 grew 150% year-over-year […]
Puma Biotechnology Reports First Quarter Financial Results
May 5, 2023 LOS ANGELES–(BUSINESS WIRE)–On May 4, Puma Biotechnology reported its earnings results for the quarter ended March 31, 2023. Go to Source Author:
Endologix Wins “Medical Device Engineering Breakthrough” Award in 7th Annual MedTech Breakthrough Awards Program
May 4, 2023 IRVINE, Calif.–(BUSINESS WIRE)– #PAD–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced today that its DETOUR™ System has been selected as the winner of the “Medical Device Engineering Breakthrough” award in the 7th annual MedTech Breakthrough Awards. This program […]
Visus Therapeutics Presents Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia at Eyecelerator @ ASCRS 2023
May 4, 2023 SEATTLE & IRVINE, Calif.–(BUSINESS WIRE)–Visus Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, today presented key topline data from the pivotal Phase 3 BRIO-I clinical trial. The study evaluating the safety and efficacy of BRIMOCHOL™ PF, a preservative-free […]
EVO ICL Sponsors Jonas Brothers’ The Tour
May 4, 2023 LAKE FOREST, Calif.–(BUSINESS WIRE)–EVO ICL, the vision correction procedure that works in harmony with your natural eye, provides sharp, clear vision day or night and does not cause contact lens induced dry eye or dry eye syndrome, announced today sponsorship of the Jonas Brothers’ The Tour in North America, which begins August […]
Glaukos Announces First Quarter 2023 Financial Results
May 3, 2023 ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2023. Key highlights include: Net sales of $73.9 million in Q1 2023 increased […]
STAAR Surgical Reports First Quarter 2023 Results
May 3, 2023 LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Overview Net Sales of $73.5 Million Up 16% and Constant Currency Net Sales of $75.5 Million Up […]
Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
May 3, 2023 PASADENA, Calif.–(BUSINESS WIRE)—- $arwr–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2023. The company is hosting a conference call today, May 2, 2023, at 4:30 p.m. ET to discuss the results. Webcast and Conference Call and Details Investors may access a live audio […]